Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as biguanides, insulin secretagogues (sulfonylureas and glinides), and alpha-glucosidase inhibitors have enjoyed high patient uptake in China due to their long market presence, physician comfort prescribing them, and favorable reimbursement. The T2D-therapy market in China will expand over the 2018-2028 forecast period, fueled by the disease’s increasing prevalence and the uptake of novel agents, particularly Johnson & Johnson’s Invokana and Sanofi’s Lyxumia. These drugs offer efficacy in lowering cardiovascular risk and eliciting weight loss, respectively, and are expected to be included in China’s NRDL. Nevertheless, despite the availability of many traditional and novel T2D agents, cost-effective therapies are still needed to improve the disease control rate, representing an opportunity for new drug developers. Additionally, with the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies are likely to be increasingly encouraged to enter the T2D-therapy market.
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary market research.
Qualitative and quantitative insights based on five country-specific interviews with thought-leading endocrinologists and supported by survey data collected for this and other DRG research.
Diagnosed prevalence of T2D with urban and rural breakup. Clinically relevant and market-relevant drug-treatable populations.
Ten-year, annualized, drug-level sales and patient shares of key T2D therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 24 agents; Phase II: 6 agents; coverage of select early-phase products.